News

Filter

Current filters:

Cardio-vascular

176 to 185 of 96546 results

Alcobra shares fall on Phase III results of ADHD drug

Alcobra shares fall on Phase III results of ADHD drug

07-10-2014

Shares of Israeli emerging biopharmaceutical company Alcobra lost nearly half their market value after…

AlcobraIsraelMetadoxineNeurologicalPharmaceuticalResearch

Sunesis’ Phase III trial in AML fails to meet primary endpoint

Sunesis’ Phase III trial in AML fails to meet primary endpoint

07-10-2014

USA-based Sunesis Pharmaceuticals says that its pivotal Phase III trial of vosaroxin and cytarabine in…

CytarabineOncologyPharmaceuticalQinprezoResearchSunesis PharmaceuticalsUSAvosaroxin

Merck Serono links with ICR and Wellcome Trust on anti-cancer drugs

Merck Serono links with ICR and Wellcome Trust on anti-cancer drugs

07-10-2014

German life sciences major Merck KGaA says its biopharma division Merck Serono has entered into a co-development…

BiotechnologyGermanyLicensingMerck KGaAMerck SeronoOncologyResearch

Regeneron gains further FDA indications for Eylea

Regeneron gains further FDA indications for Eylea

07-10-2014

The US Food and Drug Administration has approved biotech firm Regeneron Pharmaceuticals’ Eylea (aflibercept)…

BayerBiotechnologyEyleaOphthalmicsRegeneron PharmaceuticalsRegulationUSA

New UK human studies funded by £60 million investment to research Parkinson’s, addiction and immunity

New UK human studies funded by £60 million investment to research Parkinson’s, addiction and immunity

07-10-2014

Three new research programs have been funded as part of a £60 million ($96 million) investment from…

NeurologicalPharmaceuticalResearchUKUnited Kingdom

Islet and BHV sign licensing agreement for diabetes drug in development

Islet and BHV sign licensing agreement for diabetes drug in development

06-10-2014

Metabolic biopharma specialist Islet Sciences says that its merger partner, Brighthaven Ventures (BHV…

BHVBrazilBrighthaven VenturesDiabetesIslet SciencesLicensingPharmaceuticalremogliflozin

Actavis to acquire Durata Therapeutics for $675 million

Actavis to acquire Durata Therapeutics for $675 million

06-10-2014

In a move that takes it further out of its main generics business, Ireland-headquartered Actavis has…

ActavisAntibiotics and Infectious diseasesDalvanceDurata TherapeuticsIrelandMergers & AcquisitionsPharmaceutical

Brilinta preferred over clopidogrel in latest AHA/ACC guideline

Brilinta preferred over clopidogrel in latest AHA/ACC guideline

06-10-2014

Anglo-Swedish pharma major AstraZeneca today confirmed that the American Heart Association (AHA) and…

AstraZenecaBrilintaCardio-vascularClopidogrelDaiichi SankyoEli LillyPharmaceuticalprasugrelRegulationSanofiticagrelorUSA

Mylan debuts generic of ViiV’s Combivir in USA

Mylan debuts generic of ViiV’s Combivir in USA

06-10-2014

US generic drugmaker Mylan has launched of its Lamivudine and Zidovudine Tablets USP, 15mg/300mg, which…

Anti-viralsCombivirGenericsGlaxoSmithKlineMarkets & MarketingMylanUSAViiV Healthcare

176 to 185 of 96546 results

Parexel

Parexel

Back to top